Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39729 SOTERA HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 47-3531161 (State or other jurisdiction of incorporation ...

Sotera Health Company (NASDAQ:SHC) Q3 2023 Earnings Conference Call November 1, 2023 9:00 AM ET Corporate Participants Jason Peterson - Vice President and Treasurer Michael Petras - Chairman and Chief Executive Officer Jonathan Lyons - Senior Vice President and Chief Financial Officer Conference Call Participants Sean Dodge - RBC Capital Markets Patrick Donnelly - Citi Michael Polark - Wolfe Research Casey Woodring - JPMorgan Operator Good morning and welcome to the Sotera Health Third Quarter 2023 Conferen ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company ...

Sotera Health Company (NASDAQ:SHC) Q2 2023 Earnings Conference Call August 3, 2023 9:00 AM ET Corporate Participants Jason Peterson - Vice President and Treasurer Michael Petras - Chairman and Chief Executive Officer Jonathan Lyons - Chief Financial Officer Conference Call Participants Sean Dodge - RBC Capital David Windley - Jefferies Luke Sergott - Barclays Casey Woodring - JPMorgan Matthew Mishan - KeyBanc Michael Polark - Wolfe Research Operator Good morning, and welcome to the Sotera Health Second Quar ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39729 SOTERA HEALTH COMPANY (Exact name of registrant as specified in its charter) | Delaware | | 47-3531161 | ...

Financial Data and Key Metrics Changes - Total company revenues declined by 6.8% year-over-year to $221 million, with a 5.3% decline on a constant currency basis [88][84] - Adjusted EBITDA decreased by 14.6% compared to the first quarter of 2022, amounting to $98 million, with adjusted EBITDA margins at 44.6%, a decline of 410 basis points [20][24] - Adjusted EPS for the quarter was $0.13, a decrease of $0.09 from the same period last year [20][108] Business Line Data and Key Metrics Changes - Sterigenics reported a 7% revenue growth to $160 million and over 4% segment income growth to $83 million compared to the first quarter of last year [8][104] - Nelson Labs experienced a revenue decline of 2.3% to $52 million, with segment income down over 17% to $14 million [109][86] - Nordion's revenue declined approximately 75% to $9 million, driven by the timing of cobalt-60 harvest supply schedules [25][85] Market Data and Key Metrics Changes - The potential impact of the complete loss of cobalt-60 supply from Russia on total Sotera Health 2023 revenues is now estimated at 0% to 2.5% [12][105] - The company expects to see increased volumes and margin expansion throughout the year for both Sterigenics and Nelson Labs [12][106] Company Strategy and Development Direction - The company is investing in additional capacity with six active expansion projects at Sterigenics and enhancements to EO facilities in North America [4][28] - The mission of safeguarding global health remains central to the company's operations, focusing on providing critical scientific expertise and regulatory consulting [6][5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the 2023 revenue forecast despite irregular timing of Nordion's revenue, with approximately 75% expected in the second half of the year [21][22] - The company anticipates total revenues for 2023 to be in the range of $1.055 billion to $1.090 billion, representing an annual growth rate of 5% to 9% [11][106] Other Important Information - The company generated approximately $34 million of operating cash flow during the quarter, with $648 million in cash and cash equivalents as of March 31, 2023 [26][27] - Capital expenditures are expected to be in the range of $185 million to $215 million, focusing on growth and capacity expansions [28][91] Q&A Session Summary Question: Any twists and turns in the segments relative to your prior plan? - Management indicated that there were no significant changes in the outlook for the segments compared to previous expectations [15][19] Question: Can you provide clarity on Nelson Labs' volume recovery? - Management noted that the first quarter is typically the lowest for Nelson Labs, but they expect volumes to pick up as the year progresses [14][43] Question: What is the expected impact of the EPA proposed regulations? - Management acknowledged the aggressive timeline for compliance but expressed confidence in their ability to meet the new standards due to prior investments [68][70] Question: How is the company positioned regarding the cobalt-60 supply? - Management confirmed that there was no disruption in supply during the first quarter and that they are well-positioned for the year [12][105] Question: What are the expectations for pricing and inflation? - Management expects pricing to settle in the range of 3.5% to 5% per year, with Sterigenics in the middle of that range [115][95]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39729 SOTERA HEALTH COMPANY (Exact name of registrant as specified in its charter) | Delaware | | 47-3531161 | ...

Sotera Health Company (NASDAQ:SHC) Q4 2022 Earnings Conference Call February 28, 2023 9:00 AM ET Company Participants Jason Peterson - Vice President and Treasurer Michael Petras - Chairman and Chief Executive Officer Michael Biehl - Interim Chief Financial Officer Conference Call Participants Sean Dodge - RBC Capital Markets Patrick Donnelly - Citigroup Matthew Mishan - KeyBanc Capital Markets Luke Sergott - Barclays Casey Woodring - JPMorgan David Windley - Jefferies Michael Polark - Wolfe Research O ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) (Exact name of registrant as specified in its charter) Delaware 47-3531161 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 9100 South Hills Blvd, Suite 300 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39729 SOTERA HEALTH COMPANY (Exact name of registrant as specified in its charter) | Delaware | | 47-3531161 | ...